Therapeutic efficacy of renin—angiotensin blockade in patients receiving dialysis

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 5, 2009, Pages 397-405

  Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme inhibitor; Angiotensin type 1 receptor blocker; Hemodialysis; Peritoneal dialysis; Renin angiotensin system

Indexed keywords

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY DISEASES; MALE; RENAL DIALYSIS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME;

ALDOSTERONE RECEPTOR; ALISKIREN; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN CONVERTING ENZYME 2; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; FOSINOPRIL; IMIDAPRIL; LISINOPRIL; LOSARTAN; NITRENDIPINE; PERINDOPRIL; PLACEBO; SPIRONOLACTONE; TRANDOLAPRIL; VALSARTAN;

ANAPHYLAXIS; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROPOIESIS; HEART LEFT VENTRICLE HYPERTROPHY; HEMODIALYSIS PATIENT; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; MAINTENANCE THERAPY; MORTALITY; PERITONEAL DIALYSIS; POTASSIUM EXCRETION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNSPECIFIED SIDE EFFECT;

EID: 70350031621     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944709338339     Document Type: Review

References (74)

1. Agarwal, R., Lewis, R., Davis, J.L. and Becker, B. ( 2001) Lisinopril therapy for hemodialysis hypertension: hemodynamic and endocrine responses. Am J Kidney Dis 38: 1245-1250.
2. Allon, M. ( 1993) Treatment and prevention of hyperkalemia in end-stage renal disease. Kidney Int 43: 1197-1209.
3. Bolanos, L., Castro, P., Falcon, T.G., Mouzo, R. and Varela, J.M. ( 2002) Continuous intravenous sodium ferric gluconate improves efficacy in the maintenance phase of EPOrHu administration in hemodialysis patients. Am J Nephrol 22: 67-72.
4. Buter, H., Navis, G.Y., Woittiez, A.J., de Zeeuw, D. and de Jong, P.E. (1999) Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur J Clin Pharmacol 54: 953-958.
5. Cannella, G., Paoletti, E., Delfino, R., Peloso, G., Molinari, S. and Traverso, G.B. ( 1993) Regression of left ventricular hypertrophy in hypertensive dialyzed uremic patients on long-term antihypertensive therapy. Kidney Int 44: 881-886.
6. Cannella, G., Paoletti, E., Delfino, R., Peloso, G., Rolla, D. and Molinari, S. ( 1997) Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30: 659-664.
7. Charron, R.C., Leme, C.E., Wilson, D.R., Ing, T.S. and Wrong, O.M. ( 1969) The effect of adrenal steroids on stool composition, as revealed by in vivo dialysis of faeces. Clin Sci 37: 151-167.
8. Chew, C.G., Weise, M.D. and Disney, A.P. ( 1999) The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 14: 2047-2049.
9. Collins, A.J., Roberts, T.L., St Peter, W.L., Chen, S.C., Ebben, J. and Constantini, E. ( 2002) United States Renal Data System assessment of the impact of the National Kidney Foundation-Dialysis Outcomes Quality Initiative guidelines. Am J Kidney Dis 39: 784-795.
10. de Rosa, M.L., Cardace, P., Rossi, M., Baiano, A. and de Cristofaro, A. ( 2002) Comparative effects of chronic ACE inhibition and AT 1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients. J Hum Hypertens 16: 133-140.
11. de Long, M., Logan, J.L., Yong, K.C. and Lien, Y.H. ( 2005) Renin-angiotensin blockade reduces serum free testosterone in middle-aged men on haemodialysis and correlates with erythropoietin resistance. Nephrol Dial Transplant 20: 585-590.
12. Dobbie, J.W. ( 1992) Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 12: 14-27.
13. Dyadyk, A.I., Bagriy, A.E., Lebed, I.A., Yarovaya, N.F., Schukina, E.V. and Taradin, G.G. ( 1997) ACE inhibitors captopril and enalapril induce regression of left ventricular hypertrophy in hypertensive patients with chronic renal failure. Nephrol Dial Transplant 12: 945-951.
14. Ecder, T., Edelstein, C.L., Chapman, A.B., Johnson, A.M., Tison, L., Gill, E.A. et al. (1999) Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 14: 1113-1116.
15. Efrati, S., Zaidenstein, R., Dishy, V., Beberashvili, I., Sharist, M., Averbukh, Z. et al. (2002) ACE inhibitors and survival of hemodialysis patients. Am J Kidney Dis 40: 1023-1029.
16. Fang, W., Oreopoulos, D.G. and Bargman, J.M. ( 2008) Use of ACE inhibitors or angiotensin receptor blockers and survival in patients on peritoneal dialysis. Nephrol Dial Transplant 23: 3704-3710.
17. Ferrario, C.M. ( 2006) Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47: 515-521.
18. Ferrario, C.M. and Strawn, W.B. ( 2006) Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121-128.
19. Ferrario, C.M., Trask, A.J. and Jessup, J.A. ( 2005) Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289: H2281-H2290
20. Gaddam, K.K. and Oparil, S. ( 2008) Renin inhibition: should it supplant ACE inhibitors and ARBS in high risk patients? Curr Opin Nephrol Hypertens 17: 484-490.
21. Guerin, A.P., Blacher, J., Pannier, B., Marchais, S.J., Safar, M.E. and London, G.M. ( 2001) Impact of aortic stiffness attenuation on survival of patients in end-stage renal failure. Circulation 103: 987-992.
22. Guerin, A.P., Marchais, S.J., Metivier, F. and London, G.M. ( 2005) Arterial structural and functional alterations in uraemia. Eur J Clin Invest 35(Suppl. 3): 85-88.
23. Han, S.W., Won, Y.W., Yi, J.H. and Kim, H.J. ( 2007) No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant 22: 1150-1155.
24. Hatch, M. and Freel, R.W. ( 2008) Increased colonic sodium absorption in rats with chronic renal failure is partially mediated by AT 1 receptor agonism. Am J Physiol Gastrointest Liver Physiol 295: G348-G356
25. Hatch, M., Freel, R.W. and Vaziri, N.D. ( 1998a) Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol 274: F275-F282
26. Hatch, M., Freel, R.W. and Vaziri, N.D. ( 1998b) Losartan antagonism of angiotensin-II-induced potassium secretion across rat colon. Pflugers Arch 436: 717-724.
27. Herzog, C.A., Ma, J.Z. and Collins, A.J. ( 2002) Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC / AHA practice guidelines on valve selection be modified? Circulation 105: 1336-1341.
28. Hirakata, H., Iseki, K., Onoyama, K., Kumagai, H., Fujimi, S. and Omae, T. ( 1983) Long-term hemodynamic response to captopril (SQ 14,225) in hypertensive hemodialysis patients. Clin Nephrol 19: 87-91.
29. Hirakata, H., Onoyama, K., Iseki, K., Omae, T., Fujimi, S. and Kawahara, Y. ( 1981) Captopril (SQ 14225) clearance during hemodialysis treatment. Clin Nephrol 16: 321-323.
30. Ichihara, A., Hayashi, M., Kaneshiro, Y., Takemitsu, T., Homma, K., Kanno, Y. et al. (2005) Low doses of losartan and trandolapril improve arterial stiffness in hemodialysis patients. Am J Kidney Dis 45: 866-874.
31. Igarashi, Y., Suzuki, H., Imafuku, T., Saito, I. and Saruta, T. ( 1987) Hypertension in patients on chronic hemodialysis: the role of the renin-angiotensin system. Jpn Circ J 51: 479-484.
32. Imai, H., Nakamoto, H., Ishida, Y., Yamanouchi, Y., Inoue, T., Okada, H. et al. (2001) Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. Adv Perit Dial 17: 20-24.
33. Kammerl, M.C., Schaefer, R.M., Schweda, F., Schreiber, M., Riegger, G.A. and Kramer, B.K. ( 2000) Extracorporal therapy with AN 69 membranes in combination with ACE inhibition causing severe anaphylactoid reactions: still a current problem? Clin Nephrol 53: 486-488.
34. Kanno, Y., Takenaka, T., Nakamura, T. and Suzuki, H. ( 2006) Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors. Clin J Am Soc Nephrol 1: 730-737.
35. Kessler, M., Zannad, F., Lehert, P., Grunfeld, J.P., Thuilliez, C., Leizorovicz, A. et al. (2007) Predictors of cardiovascular events in patients with end-stage renal disease: an analysis from the Fosinopril in dialysis study. Nephrol Dial Transplant 22: 3573-3579.
36. Kimura, G., Takahashi, N., Kawano, Y., Inenaga, T., Inoue, T., Nakamura, S. et al. (1995) Plasma renin activity in hemodialyzed patients during long-term follow-up. Am J Kidney Dis 25: 589-592.
37. Knoll, G.A., Sahgal, A., Nair, R.C., Graham, J., van Walraven, C. and Burns, K.D. (2002) Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 112: 110-114.
38. Li, P.K., Chow, K.M., Wong, T.Y., Leung, C.B. and Szeto, C.C. ( 2003) Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study. Ann Intern Med 139: 105-112.
39. London, G.M. ( 2001) Vascular disease and atherosclerosis in uremia. Blood Purif 19: 139-142.
40. London, G.M. ( 2005) Vascular disease and atherosclerosis in uremia. Nefrologia 25(Suppl. 2): 91-95.
41. Losito, A., Kalidas, K., Santoni, S., Ceccarelli, L. and Jeffery, S. ( 2002) Polymorphism of renin-angiotensin system genes in dialysis patients-association with cerebrovascular disease. Nephrol Dial Transplant 17: 2184-2188.
42. Luik, A.J., van Kuijk, W.H., Spek, J., de Heer, F., van Bortel, L.M., Schiffers, P.M. et al. (1997) Effects of hypervolemia on interdialytic hemodynamics and blood pressure control in hemodialysis patients. Am J Kidney Dis 30: 466-474.
43. Macdougall, I.C. ( 1999) The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin. Nephrol Dial Transplant 14: 1836-1841.
44. Matsumoto, N., Ishimitsu, T., Okamura, A., Seta, H., Takahashi, M. and Matsuoka, H. ( 2006) Effects of imidapril on left ventricular mass in chronic hemodialysis patients. Hypertens Res 29: 253-260.
45. McCullough, P.A., Sandberg, K.R., Yee, J. and Hudson, M.P. ( 2002) Mortality benefit of angiotensin-converting enzyme inhibitors after cardiac events in patients with end-stage renal disease. J Renin Angiotensin Aldosterone Syst 3: 188-191.
46. McLaughlin, N., Gehr, T.W. and Sica, D.A. ( 2004) Aldosterone-receptor antagonism and end-stage renal disease. Curr Hypertens Rep 6: 327-330.
47. Meeus, F., Kourilsky, O., Guerin, A.P., Gaudry, C., Marchais, S.J. and London, G.M. ( 2000) Pathophysiology of cardiovascular disease in hemodialysis patients. Kidney Int Suppl 76: S140-S147
48. Musini, V.M., Fortin, P.M., Bassett, K. and Wright, J.M. ( 2008) Blood pressure lowering efficacy of renin inhibitors for primary hypertension. Cochrane Database Syst Rev CD007066.
49. Ottosson, P., Attman, P.O., Agren, A.C. and Samuelsson, O. ( 2003) Candesartan cilexetil in haemodialysis patients. Clin Drug Investig 23: 545-550.
50. Paoletti, E., Cassottana, P., Bellino, D., Specchia, C., Messa, P. and Cannella, G. ( 2002) Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 40: 728-736.
51. Pfister, M., Schaedeli, F., Frey, F.J. and Uehlinger, D.E. ( 1999) Pharmacokinetics and haemodynamics of candesartan cilexetil in hypertensive patients on regular haemodialysis. Br J Clin Pharmacol 47: 645-651.
52. Phakdeekitcharoen, B. and Leelasa-nguan, P. ( 2004) Effects of an ACE inhibitor or angiotensin receptor blocker on potassium in CAPD patients. Am J Kidney Dis 44: 738-746.
53. Raizada, V., Skipper, B., Luo, W., Garza, L., Hines, C.W., Harford, A.A. et al. (2005) Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int 68: 1186-1189.
54. Roithinger, F.X., Punzengruber, C., Wallner, M., Ulbrich, W., Pachinger, O., Kramar, R. et al. (1994) The influence of ACE-inhibition on myocardial mass and diastolic function in chronic hemodialysis patients with adequate control of blood pressure. Clin Nephrol 42: 309-314.
55. Rostoker, G., Griuncelli, M. and Benmaadi, A. ( 2006) Candesartan cilexetil on regular hemodialysis: inability to reduce excessive thirst, but good tolerance and efficacy in hypertensive patients. Ren Fail 28: 283-286.
56. Ruiz-Ortega, M., Ruperez, M., Esteban, V., Rodriguez-Vita, J., Sanchez-Lopez, E., Carvajal, G. et al. (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21: 16-20.
57. Sandle, G.I., Gaiger, E., Tapster, S. and Goodship, T.H. ( 1987) Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 73: 247-252.
58. Saracho, R., Martin-Malo, A., Martinez, I., Aljama, P. and Montenegro, J. ( 1998) Evaluation of the Losartan in Hemodialysis (ELHE) Study. Kidney Int Suppl 68: S125-S129
59. Schaefer, R.M., Schaefer, L. and Horl, W.H. ( 1994) Anaphylactoid reactions during hemodialysis. Clin Nephrol 42(Suppl. 1): S44-S47
60. Schiffl, H. and Lang, S.M. ( 1999) Angiotensin-converting enzyme inhibitors but not angiotensin II AT 1 receptor antagonists affect erythropoiesis in patients with anemia of end-stage renal disease. Nephron 81: 106-108.
61. Shibasaki, Y., Masaki, H., Nishiue, T., Nishikawa, M., Matsubara, H. and Iwasaka, T. ( 2002) Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 90: 256-261.
62. Suzuki, H., Kanno, Y., Kaneko, K., Kaneko, M., Kotaki, S., Mimura, T. et al. (2004) Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy. Ther Apher Dial 8: 320-327.
63. Suzuki, H., Kanno, Y., Sugahara, S., Ikeda, N., Shoda, J., Takenaka, T. et al. (2008) Effect of angiotensin receptor blockers on cardiovascular events in patients undergoing hemodialysis: an open-label randomized controlled trial. Am J Kidney Dis 52: 501-506.
64. Suzuki, H., Kanno, Y., Sugahara, S., Okada, H. and Nakamoto, H. ( 2004) Effects of an angiotensin II receptor blocker, valsartan, on residual renal function in patients on CAPD. Am J Kidney Dis 43: 1056-1064.
65. Suzuki, H., Nakamoto, H., Okada, H., Sugahara, S. and Kanno, Y. ( 2003) A selective angiotensin receptor antagonist, Valsartan, produced regression of left ventricular hypertrophy associated with a reduction of arterial stiffness. Adv Perit Dial 19: 59-66.
66. Takahashi, A., Takase, H., Toriyama, T., Sugiura, T., Kurita, Y., Ueda, R. et al. (2006) Candesartan, an angiotensin II type-1 receptor blocker, reduces cardiovascular events in patients on chronic haemodialysis - a randomized study. Nephrol Dial Transplant 21: 2507-2512.
67. Tepel, M., van der Giet, M. and Zidek, W. ( 2001) Efficacy and tolerability of angiotensin II type 1 receptor antagonists in dialysis patients using AN 69 dialysis membranes. Kidney Blood Press Res 24: 71-74.
68. Toto, R., Shultz, P., Raij, L., Mitchell, H., Shaw, W., Ramjit, D. et al. (1998) Efficacy and tolerability of losartan in hypertensive patients with renal impairment. Collaborative Group. Hypertension 31: 684-691.
69. Wauters, J.P., Waeber, B., Brunner, H.R., Guignard, J.P., Turini, G.A. and Gavras, H. ( 1981) Uncontrollable hypertension in patients on hemodialysis: long-term treatment with captopril and salt subtraction. Clin Nephrol 16: 86-92.
70. Weidmann, P., Maxwell, M.H., Lupu, A.N., Lewin, A.J. and Massry, S.G. ( 1971) Plasma renin activity and blood pressure in terminal renal failure. N Engl J Med 285: 757-762.
71. Wetmore, J.B., Johansen, K.L., Sen, S., Hung, A.M. and Lovett, D.H. ( 2006) An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet 120: 201-210.
72. Yu, W.C., Lin, Y.P., Lin, I.F., Chuang, S.Y. and Chen, C.H. ( 2006) Effect of ramipril on left ventricular mass in normotensive hemodialysis patients. Am J Kidney Dis 47: 478-484.
73. Zannad, F., Kessler, M., Lehert, P., Grunfeld, J.P., Thuilliez, C., Leizorovicz, A. et al. (2006) Prevention of cardiovascular events in end-stage renal disease: results of a randomized trial of fosinopril and implications for future studies. Kidney Int 70: 1318-1324.
74. Zheng, S., Nath, V. and Coyne, D.W. ( 2007) ACE inhibitor-based, directly observed therapy for hyper- ht tension in hemodialysis patients. Am J Nephrol 27: 522-529.